A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (NCT03682536)

🧪 Interventions in This Study

• Luspatercept (DRUG)
• Epoetin alfa (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (226 Sites)

Showing the first 25 of 226 sites.

• Local Institution - 107 — Berkeley, California
• Local Institution - 115 — San Diego, California
• Local Institution - 101 — Whittier, California
• Local Institution - 104 — New Haven, Connecticut
• Local Institution - 136 — Washington D.C., District of Columbia
• Local Institution - 119 — Hudson, Florida
• Local Institution - 120 — St. Petersburg, Florida
• Local Institution - 122 — Tallahassee, Florida
• Local Institution - 108 — Tampa, Florida
• Local Institution - 118 — West Palm Beach, Florida
• Local Institution - 102 — Paducah, Kentucky
• Local Institution - 123 — Bethesda, Maryland
• Local Institution - 117 — Kansas City, Missouri
• Local Institution - 134 — East Brunswick, New Jersey
• Local Institution - 113 — Hackensack, New Jersey
• Local Institution - 105 — Greenville, North Carolina
• Local Institution - 131 — Portland, Oregon
• Univ of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
• Local Institution - 111 — Rock Hill, South Carolina
• Tennessee Oncology — Nashville, Tennessee
• Baylor University Medical Center — Dallas, Texas
• Local Institution - 109 — Houston, Texas
• Local Institution - 114 — Salt Lake City, Utah
• Local Institution - 132 — Charlottesville, Virginia
• Local Institution - 127 — Chesapeake, Virginia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Myelodysplastic Syndromes

• ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions — Clovis, California
• Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA — Tampa, Florida
• A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) — Lakewood, California
• Inqovi Maintenance Therapy in Myeloid Neoplasms — Boston, Massachusetts
• Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) — Birmingham, Alabama
• CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome — Tampa, Florida

Explore by condition: All Myelodysplastic Syndromes clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.